Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chemotherapy-Induced Myelosuppression”

22 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 22 results

Early research (Phase 1)Ended earlyNCT00238173
What this trial is testing

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

Who this might be right for
Bone Marrow SuppressionBrain and Central Nervous System TumorsDrug/Agent Toxicity by Tissue/Organ+1 more
OHSU Knight Cancer Institute 2
Testing effectiveness (Phase 2)Study completedNCT02692742
What this trial is testing

Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia

Who this might be right for
Chemotherapy-Induced NeutropeniaMyelosuppressionBreast Cancer
Myelo Therapeutics GmbH 137
Post-approval studies (Phase 4)Looking for participantsNCT05874401
What this trial is testing

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Who this might be right for
Extensive-stage Small-cell Lung Cancer
Pharmacosmos A/S 302
Large-scale testing (Phase 3)Study completedNCT04799249
What this trial is testing

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

Who this might be right for
TNBC - Triple-Negative Breast CancerBreast Cancer
G1 Therapeutics, Inc. 194
Post-approval studies (Phase 4)Study completedNCT05071703
What this trial is testing

Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study

Who this might be right for
Extensive-stage Small-cell Lung Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd. 30
Early research (Phase 1)Study completedNCT00005796
What this trial is testing

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

Who this might be right for
Bone Marrow SuppressionBrain and Central Nervous System TumorsDrug/Agent Toxicity by Tissue/Organ
Indiana University 10
Early research (Phase 1)Ended earlyNCT04022876
What this trial is testing

ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

Who this might be right for
Non Small Cell Lung CancerSmall-cell Lung Cancer
Aileron Therapeutics, Inc. 35
Testing effectiveness (Phase 2)WithdrawnNCT03692780
What this trial is testing

Careseng 1370 for Chemotherapy-Induced Myelosuppression

Who this might be right for
Chemotherapy-Induced Myelosuppression
Careseng Biotech Co., Ltd.
Testing effectiveness (Phase 2)UnknownNCT05672420
What this trial is testing

Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies

Who this might be right for
Hematologic NeoplasmsNeutropeniaAnemia+3 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 181
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06714266
What this trial is testing

Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)
Shandong Cancer Hospital and Institute 30
Testing effectiveness (Phase 2)Ended earlyNCT04887831
What this trial is testing

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

Who this might be right for
Urothelial CarcinomaBladder CancerMyelosuppression Adult+2 more
G1 Therapeutics, Inc. 92
Not applicableUnknownNCT02663492
What this trial is testing

Transcutaneous Electrical Acupoint Stimulation for Non-small Cell Lung Cancer Patients

Who this might be right for
Non-Small Cell Lung CancerLung Cancer
Tongji University 300
Early research (Phase 1)Ended earlyNCT05622058
What this trial is testing

ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

Who this might be right for
Prevention of Chemotherapy-induced Myelosuppression
Aileron Therapeutics, Inc. 6
Early research (Phase 1)Looking for participantsNCT06245746
What this trial is testing

UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaNeutropeniaAnemia+3 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 9
Not applicableStudy completedNCT05442177
What this trial is testing

Clinical Observation of Integrated Chinese Medicine With Western Medicine for the Reduction of Chemotherapy-induced Hematologic Toxicity

Who this might be right for
Myelosuppression
Taichung Tzu Chi Hospital 35
Early research (Phase 1)Ended earlyNCT03974516
What this trial is testing

Careseng 1370 for Healthy Volunteers

Who this might be right for
Chemotherapy-induced Myelosuppression
i Cure Biotech Co., Ltd. 13
Not applicableUnknownNCT03846414
What this trial is testing

Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia

Who this might be right for
Chemotherapy-induced NeutropeniaMyelosuppression
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. 1,500
Post-approval studies (Phase 4)UnknownNCT03793205
What this trial is testing

G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients

Who this might be right for
Gynecologic CancerMyelosuppression AdultFebrile Neutropenia+1 more
Lei Li 100
Large-scale testing (Phase 3)Ended earlyNCT04607668
What this trial is testing

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

Who this might be right for
Colorectal Cancer MetastaticMyelosuppression-AdultChemotherapeutic Toxicity
G1 Therapeutics, Inc. 326
Not applicableApproved For MarketingNCT04504513
What this trial is testing

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

Who this might be right for
Myelosuppression AdultChemotherapeutic ToxicitySmall Cell Lung Cancer
G1 Therapeutics, Inc.
Load More Results